Could a common painkiller boost lung cancer treatment?
NCT ID NCT04184921
First seen Feb 03, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study looked at adding aspirin to the targeted drug osimertinib for people with advanced EGFR-positive lung cancer who had not yet received treatment. The goal was to see if the combination could help control the cancer longer and delay drug resistance. 216 participants were enrolled across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER NON-SMALL CELL STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Daping Hospital
Chongqing, Chongqing Municipality, 400000, China
Conditions
Explore the condition pages connected to this study.